Updates

** Shares of medical device maker Abbott Laboratories ABT.N fall 7.3% to $122.11 premarket

** Abbott forecasts Q3 adj profit between $1.28 and $1.32 per share vs analysts' average estimate of $1.34 per share, according to data compiled by LSEG

** Company posts Q2 profit of $1.26 per share compared with analysts' estimate of $1.25 per share

** Reports Q2 revenue of $11.1 billion in line with expectations

** Its medical device business reports sales of $5.37 billion, above estimates of $5.24 billion

** Abbott expects headwind of around $700 million on 2025 sales growth in diagnostics

** RBC Capital Markets says it is disappointed with the 2025 outlook, but "believe that 7.5% year on year underlying growth with double-digit EPS growth for the business in Q2 is notable off of its large revenue base with impressive ongoing strength in diabetes"

** Leerink Partners sees reasons "to be encouraged with its MedTech segment delivering better-than-expected growth with broad-based strength during the quarter"

** Including session's moves, stock up 11.5% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))